LY-2599506

DB05970InvestigationalSmall molecule

LY2599506 was under investigation in clinical trials NCT01024244 and NCT01029795 for the treatment of patients with type 2 diabetes.

Chemical structure of LY-2599506
Primary indication
Investigated for use/treatment in diabetes mellitus type 1 and 2.Curator reviewed
Formula / weight
C21H25N3O4S · 415.51 g/mol (avg)
Also known as
(R)-2-(4-(CYCLOPROPYLSULFONYL)PHENYL)-N-(PYRAZIN-2-YL)-3-(TETRAHYDRO-2H-PYRAN-4-YL)PROPANAMIDE
Code names
DB-257971 · LY-2599506 · PSN-010

Resolves to

Compound
UNIIW4S5EBH81CCAS745051-65-4
Structure
InChIKeyDQIITKNITDKAJZ-LJQANCHMSA-NSMILESO=C(NC1=CN=CC=N1)[C@H](CC1CCOCC1)C1=CC=C(C=C1)S(=O)(=O)C1CC1
Targets
P35557GCK

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with LY-2599506, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In